Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice].

Recenti progressi in medicina - 1 Dec 2025

Belluomini Lorenzo, Pilotto Sara

Abstract excerpt

The aim of this work is to provide an updated overview of the use of sotorasib in advanced NSCLC harboring KRAS G12C mutations, summarizing both clinical trial and real-world evidence supporting its use in pretreated patients. The analysis focuses on efficacy, safety, and management of key toxicities, with particular attention to hepatic adverse events. Specific emphasis is also placed on intracranial activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Piperazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Precision Medicine

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Share to Triazoles

Source

Identifiers

PMID: 41392795
DOI: 10.1701/4619.46290

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice].PMID 41392795Read ↗

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.Semantic proximity Read ↗

[Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].Semantic proximity Read ↗

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.Semantic proximity Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.Semantic proximity Read ↗

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer.Semantic proximity Read ↗

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.Semantic proximity Read ↗

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.